Ophthotech Corp (NASDAQ:OPHT) insider David R. Guyer sold 3,798 shares of Ophthotech stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $3.17, for a total transaction of $12,039.66. Following the sale, the insider now owns 42,458 shares of the company’s stock, valued at $134,591.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Ophthotech Corp (OPHT) traded up $0.06 during mid-day trading on Friday, hitting $2.85. 229,639 shares of the company’s stock traded hands, compared to its average volume of 464,522. The stock has a market capitalization of $102.71, a P/E ratio of 1.83 and a beta of 1.58. Ophthotech Corp has a 52-week low of $2.24 and a 52-week high of $5.05.
Several brokerages have issued reports on OPHT. TheStreet upgraded shares of Ophthotech from an “e+” rating to a “c” rating in a research report on Thursday, November 30th. ValuEngine lowered shares of Ophthotech from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Stifel Nicolaus reissued a “hold” rating and set a $4.00 price target on shares of Ophthotech in a research note on Thursday, September 21st. Finally, Zacks Investment Research raised shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target on the stock in a research note on Monday, November 13th.
Hedge funds have recently bought and sold shares of the business. Federated Investors Inc. PA increased its stake in shares of Ophthotech by 102.3% in the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 28,040 shares during the period. Schwab Charles Investment Management Inc. increased its position in Ophthotech by 73.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 49,928 shares during the period. Geode Capital Management LLC increased its position in Ophthotech by 3.2% during the 1st quarter. Geode Capital Management LLC now owns 240,571 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 7,501 shares during the period. First Manhattan Co. purchased a new position in Ophthotech during the 3rd quarter valued at $1,201,000. Finally, Goldman Sachs Group Inc. increased its position in Ophthotech by 28.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock valued at $1,672,000 after purchasing an additional 143,349 shares during the period. 62.48% of the stock is currently owned by hedge funds and other institutional investors.
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.